Syndax Pharmaceuticals (SNDX) Expected to Announce Quarterly Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX) will likely be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 6th. Analysts expect Syndax Pharmaceuticals to post earnings of ($1.24) per share and revenue of $15.88 million for the quarter.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $13.42 on Tuesday. The firm has a 50 day simple moving average of $13.05 and a 200-day simple moving average of $14.81. The stock has a market capitalization of $1.15 billion, a PE ratio of -3.70 and a beta of 1.28. Syndax Pharmaceuticals has a 12-month low of $9.66 and a 12-month high of $25.07.

Insider Activity at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,683 shares of company stock valued at $336,087. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SNDX shares. HC Wainwright reaffirmed a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Scotiabank cut their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Citigroup reduced their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. boosted their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th. Finally, StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a research note on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).